You are here:

Archived: infliximab (Remicade)


In the absence of a submission from the holder of the marketing authorisation.

infliximab (Remicade) is not recommended for use within NHSScotland for the treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: infliximab (Remicade)
SMC Drug ID: 374/07
Manufacturer: Schering-Plough Ltd
Indication: moderately to severely active ulcerative colitis.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 7 May 2007

Current Advice

Resubmission 12 May 2014